SOURCE: Oxford Biomedica Plc

May 12, 2005 05:41 ET

Oxford Biomedica Plc - 2005 ASCO Annual Meeting

OXFORD, UK -- (MARKET WIRE) -- May 12, 2005 --

FOR IMMEDIATE RELEASE                                  12 MAY 2005

                        ANNUAL MEETING ON 15 MAY

Oxford, UK: 12 May 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy company, today announced that new data from the Phase II trials of TroVax, its cancer immunotherapy, in colorectal cancer will be presented on 15 May at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Orlando, Florida, USA, on 13-17 May 2005. Details are as follows:

"An Open Label Phase II Study of MVA Expressing the Tumour Antigen 5T4 Given in Conjunction with Chemotherapy: Safety and Immunogenicity Before, During and After Chemotherapy." (Abstract #30642)

Session: Developmental Therapeutics, Immunotherapy
Sunday 15 May, 8:00 am - 12:00 noon, Level 2, Hall C, H10

This abstract may be accessed online at at the conclusion of the meeting.

The presentation describes two Phase II trials of TroVax in first line treatment of metastatic colorectal cancer alongside irinotecan-based (IFL) and oxaliplatin-based (FOLFOX) chemotherapy. Oxford BioMedica previously reported encouraging results from the trials in March 2005. The new data include analysis of immune responses and clinical benefit.

Enrolment in the trials was completed in September 2004 with 36 patients recruited. The trials are on track to report full safety and immunological data as well as final tumour response statistics in the second half of 2005. Patient survival, which can be compared to historical controls, will be reported once the median survival has been reached in the two trials. This is anticipated in early 2006.

Commenting on the ASCO presentation of Phase II results for TroVax, Oxford BioMedica's Chief Scientific Officer, Dr Sue Kingsman, said: "We are very pleased with the progress of TroVax in clinical trials and look forward to presenting new data at ASCO".


For further information, please contact:

Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive        Tel: +44 (0)1865 783 000

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson
Buchanan Communications                         Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:
Sue Charles/ Katja Stout/ Ashley Lilly
Northbank Communications                        Tel: +44 (0)20 7886 8150
Notes to editors:

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company's lead product is a gene therapy for Parkinson's disease, which is expected to enter clinical trials in early 2006, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 65 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham, Viragen, MolMed and Kiadis; and has licensed technology to a number of companies including Merck & Co and Biogen Idec.

Further information is available at

2. TroVax® cancer immunotherapy

TroVax is Oxford BioMedica's leading cancer immunotherapy product. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a poxvirus (MVA) gene transfer system, which delivers the gene for 5T4 and stimulates a patient's body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4 protein.

In Phase I/II trials in late stage colorectal cancer patients, TroVax was safe and well tolerated; patients mounted an anti-5T4 immune response; and the immune response correlated, with high significance, to time to disease progression, which translated into a correlation with improved overall survival.

Four Phase II trials are underway. Positive initial data from trials investigating TroVax in colorectal cancer in combination with first line standard of care treatment and as a (neo) adjuvant to surgery were released in March 2005. The primary endpoints of safety and immunological responses were achieved. In the two trials of TroVax alongside chemotherapy, the secondary endpoint of tumour response rate exceeded expectation.

A further Phase II trial is ongoing in renal cell carcinoma, and the US National Cancer Institute, through the Southwest Oncology Group, is planning a Phase II trial in breast cancer.


The American Society of Clinical Oncology is the world's leading professional organisation representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the many different cancers that strike millions of people around the world every year.

             This information is provided by RNS
    The company news service from the London Stock Exchange